What is Erste Group Bank’s Estimate for JNJ FY2027 Earnings?

Johnson & Johnson (NYSE:JNJ) – Analysts at Erste Group Bank boosted their FY2027 earnings per share (EPS) estimates for shares of Johnson & Johnson in a research report issued on Tuesday, March 24th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $12.54 per share for the year, up from their previous estimate of $12.50. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.58 per share.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The business had revenue of $24.28 billion for the quarter.

Several other analysts also recently commented on the stock. UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. Stifel Nicolaus raised their target price on shares of Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Sanford C. Bernstein increased their price target on Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research report on Friday, January 23rd. Finally, Morgan Stanley set a $253.00 price objective on Johnson & Johnson in a research note on Wednesday, March 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $236.91.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $239.93 on Thursday. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The company has a market cap of $577.90 billion, a PE ratio of 21.71, a price-to-earnings-growth ratio of 2.32 and a beta of 0.34. The company’s 50 day moving average is $236.58 and its 200 day moving average is $209.82.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 30,142 shares of company stock worth $7,360,528 over the last 90 days. Insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

Institutional investors have recently added to or reduced their stakes in the stock. Blueline Advisors LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at $25,000. Abich Financial Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the third quarter worth about $26,000. Cresta Advisors Ltd. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $26,000. Evolution Wealth Management Inc. purchased a new position in Johnson & Johnson in the 2nd quarter valued at about $27,000. Finally, Clayton Financial Group LLC acquired a new stake in Johnson & Johnson in the 3rd quarter worth about $28,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Punitive damages of about $950 million in a talc-related case were overturned, materially reducing near‑term litigation exposure and uncertainty for JNJ. Punitive Damages Award Overturned
• Positive Sentiment: Phase 1 results for an extended‑release erdafitinib delivery system in non‑muscle‑invasive bladder cancer showed very high response rates (reportedly ~89%), supporting upside to the Innovative Medicines pipeline if later‑stage data confirm benefits. Bladder Cancer Trial Results
• Positive Sentiment: Medtech momentum: JNJ reported FDA approval for the TECNIS PureSee intraocular lens and highlighted procedure‑area advances that could add recurring, higher‑margin revenue in ophthalmology and procedures. Procedure & Vision Advances
• Positive Sentiment: Technical and analyst sentiment remains constructive: JNJ has traded above its 50‑ and 200‑day moving averages for months and brokers/media pieces are highlighting it as a defensive, innovation‑led buy, supporting demand from yield‑and‑quality oriented investors. Technical/Broker Commentary
• Positive Sentiment: Partnerships/pipeline expansion: a collaboration (Protagonist) was highlighted as part of JNJ’s effort to compete in immunology, which could bolster longer‑term growth prospects. Protagonist Partnership
• Neutral Sentiment: Market narratives and strategy pieces continue to cast JNJ as a defensive, dividend‑king stock with innovation upside — useful framing for long‑term investors but less directly catalytic than clinical or legal events.
• Negative Sentiment: Residual talc litigation remains: a $16 million talc verdict was upheld in a recent case, and media mentions of JNJ as “overvalued” could pressure sentiment if litigation headlines resume. Talc Verdict Stands

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.